Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 14 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				CEPO906A2303 NCT00262990


2.		EPO906 in Patients With Late Stage Non-Small-Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				CEPO906A 2209 NCT00088127


3.		Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				3c-03-19 NCT00159484


4.		Study of Patupilone in Patients With Brain Metastasis From Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				CEPO906A2227 NCT00219297


5.		Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				OZM-005/CEPO906A2402 Protocol number CEP0906A2402, OZM-005, NCT00407251


6.		Efficacy and Safety of Patupilone in Men (=18 Years) With Metastatic Hormone Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				CEPO906A2229 NCT00411528

Last Modified: 6/27/2007 First Published: 3/16/2007


7.		Phase II Study of Epothilone B in Patients With CNS Metastases Secondary to Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				CASE-5106 CASE-IRB-5106-CC185, CASE 5106, NCT00450866, MSKCC-07036


8.		EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Other				03C.275 NCT00328458


9.		A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Pharmaceutical / Industry				CEPO906A2121 NCT00420524


10.		Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Pharmaceutical / Industry				CEPO906A2123 NCT00420615

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute